IMR Press / FBL / Special Issues / upper_gastrointestinal_malignancies

Advances in Upper Gastrointestinal Malignancies Research

Submission deadline: 31 October 2022
Special Issue Editor
  • Ulrich Ronellenfitsch, MD
    Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Germany
    Interests: upper gastrointestinal cancer; multimodal treatment; gastrectomy; esophagectomy; sarcoma; quality of care; meta-analysis
Special Issue Information

Dear Colleagues,

The treatment of upper gastrointestinal malignancies, i.e. tumors of the esophagus and stomach, has seen remarkable advances over the past few decades. Chemotherapy, immunotherapy, targeted therapy with antibodies or biologicals, and radiotherapy have expanded the available therapeutic options beyond mere surgical resection. The latter, however, remains the only potentially curative modality for many upper gastrointestinal malignancies. Surgical techniques have also undergone landmark developments in recent years, with minimally invasive or robotic approaches now being a mainstay in many settings. The ideal combination and temporal sequence of treatments is being evaluated in clinical trials and is constantly evolving. Researchers from all involved fields collaborate on trials, which nowadays increasingly include patient-centered endpoints beyond survival, such as quality of life and functional outcomes. The ultimate aim of these trials is to improve the wellbeing and outcome of patients with upper gastrointestinal malignancies. 

Frontiers in Bioscience-Landmark will publish a Special Issue titled Advances in Upper Gastrointestinal Malignancies Research. The aim of this special issue is to cover all facets of research relating to upper gastrointestinal malignancies, with a focus on potential clinical implications. Submissions containing original pre-clinical and clinical research, short communications, meta-analyses and review articles are all welcome.

I invite you to submit your articles before the deadline indicated above.

Prof. Ulrich Ronellenfitsch

Guest Editor

Keywords
upper gastrointestinal cancer
chemotherapy
radiotherapy
surgery
immunotherapy
targeted therapy
multimodal treatment
esophageal cancer
stomach cancer
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top